Skip to main content
David Siegel, MD, Oncology, Hackensack, NJ

DavidSSiegelMDPhD

Oncology Hackensack, NJ

Hematologic Oncology

Chief, Myeloma Division John Theurer Cancer Center, Hackensack University Medical Center. Founding Director, Institute for Multiple Myeloma. Center for Discovery and Innovation

Dr. Siegel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Siegel's full profile

Already have an account?

  • Office

    92 2nd St
    Hackensack, NJ 07601
    Phone+1 551-996-8704
    Fax+1 551-996-0582

Summary

  • Dr. David Siegel is an oncologist in Hackensack, NJ and is affiliated with multiple hospitals in the area, including Hackensack Meridian Health Hackensack University Medical Center and MedStar Georgetown University Hospital. He received his medical degree from NYU School of Medicine and has been in practice 31 years. He specializes in hematologic oncology and is experienced in multiple myeloma, bone marrow transplant, AL amyloidosis and Waldenstroms Macroglobulinemia.
  • David Siegel, M.D., PhD, conducts critical research to develop new treatments fo

    Dr. David Siegel, chief of the Myeloma Division and director of the Institute for Multiple Myeloma at John Theurer Cancer Center, treats patients with multi...

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineResidency, Internal Medicine, 1987 - 1989
  • NYU Grossman School of Medicine
    NYU Grossman School of MedicineInternship, Internal Medicine, 1986 - 1987
  • New York University School of Medicine
    New York University School of MedicineClass of 1986
  • New York University
    New York UniversityPhD, 1985
  • New York University
    New York UniversityMSc, 1984
  • American Association of Immunologists
    American Association of ImmunologistsCertificate, Advanced Immunology Course, 1984
  • Cook College, Rutgers University
    Cook College, Rutgers UniversityB.S., With Honors, 1979

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 2024 - 2027
  • NH State Medical License
    NH State Medical License 2024 - 2026
  • NY State Medical License
    NY State Medical License 1987 - 2026
  • OH State Medical License
    OH State Medical License 2024 - 2026
  • VT State Medical License
    VT State Medical License 2024 - 2026
  • CO State Medical License
    CO State Medical License 2024 - 2025
  • CT State Medical License
    CT State Medical License 2024 - 2025
  • American Board of Internal Medicine Internal Medicine
  • Join now to see all

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FACP) American College of Physicians, 2002
  • Young Investigator Award ASCO, 1991
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR  
    Ruben Niesvizky, David Siegel, Ralph Boccia, Blood
  • Updated survival analyses after prolonged follow-up of the phase 2, multicenter CReST study of bortezomib in relapsed or refractory multiple myeloma  
    Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG,Niesvizky R, Alexanian R, Limentani SA, Alsina M, esseltine DL, Anderson KC, Br J Haematol, 1/1/2014
  • Phase I Trial of Anti-CS1 Monoclonal Antibody elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma  
    Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar De, Singhal AK, Anderson KC, J Clin Oncol, 1/30/2012
  • Join now to see all

Books/Book Chapters

Lectures

  • CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Immunogenomics Is on the Way Up
    Immunogenomics Is on the Way UpAugust 12th, 2024
  • First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
    First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple MyelomaNovember 20th, 2019
  • FDA Approves Kyprolis (Carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple Myeloma
    FDA Approves Kyprolis (Carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple MyelomaNovember 29th, 2011
  • Join now to see all

Committees

  • Working Group Member, International Waldenstrom's Macroglobulenemia Working Group 2011 - 2016
  • Steering Committee, MMRF 2005 - 2016
  • group Member, International Myeloma Working Group 2005 - 2016

Research History

  • Chief, Myeloma Division12 current clinical trials2002 - 2016

Professional Memberships